ClinConnect ClinConnect Logo
Search / Trial NCT00976846

Investigation of Performance and Compatibility of the Baxter Dialyzer Xenium XPH 210 During On-line Hemodiafiltration

Launched by PRAXISVERBUND DIALYSE UND APHERESE · Sep 14, 2009

Trial Information

Current as of May 06, 2025

Completed

Keywords

Hemodialysis On Line Postdilution High Flux Dialyzer Hemodiafiltration

ClinConnect Summary

The new high flux dialyser membrane Xenium XPH 210 from Baxter will show an considerably increased removal of ß2-Microglobulin with olHDF in post dilution mode together with a markedly increased removal of small molecules (urea, creatinine, phosphate). The loss of albumin will depend on the treatment modalities. However, the albumin permeability is tolerable over the whole range of total filtration rate selected and applied to the patients.

Together with the albumin loss into the filtrate/dialysate a small amount of albuminbound substances is detectable.

Parameters of micro-inflammation c...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who have signed an informed consent form.
  • Patients between 18 and 75 years.
  • Patients who have been treated with hemodialysis for more than three months.
  • Patients who are treated three times a week for 4-5 hours.
  • Patients who are usually treated with high-flux dialyzers.
  • Patients who are on a stable anticoagulation and erythropoetin regimen.
  • Patients whose hematocrit is over 28 %.
  • Patients having no vascular access related problems.
  • Exclusion Criteria:
  • Patients not meeting the inclusion criteria.
  • Patients who are in a poor nutritional status as judged by the investigator.
  • Patients in a gravid state.
  • Patients with an unstable clinical condition (e.g. cardiac or vascular instability).
  • Patients whose life expectancy is less than 12 months.
  • Patients with a positive anamnesis for the first use syndrome.
  • Patients with known coagulation problems.
  • Patients who receive hemodialysis via a single dialysis needle or central venous catheter.
  • Patients participating in another study that may interfere with the outcome of the present study.

About Praxisverbund Dialyse Und Apherese

Praxisverbund Dialyse und Apherese is a leading clinical trial sponsor specializing in the fields of nephrology and apheresis therapies. Committed to advancing patient care, the organization focuses on innovative research that enhances treatment outcomes for individuals with renal conditions. Through collaborative partnerships with healthcare professionals and research institutions, Praxisverbund Dialyse und Apherese aims to facilitate rigorous clinical trials that adhere to the highest ethical and scientific standards. Their dedication to evidence-based practices and patient-centered research positions them as a trusted entity in the clinical research landscape.

Locations

Rostock, , Germany

Patients applied

0 patients applied

Trial Officials

Peter G. Ahrenholz, PhD

Principal Investigator

BioArtProducts GmbH Rostock, Germany

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials